Exclusive Summary

• - Patent barrier largely cleared: Core Velcade IP expired in US/EU in 2017/2019, making major markets fully generic and ready for distribution-led entry.
• - Stable, needs-driven demand: Multiple myeloma sees ~176k new cases/year and ~488k 5-year prevalence globally, with long treatment courses and steady vial consumption.
• - Solid clinical position: Listed on the WHO Model List; NCCN/ESMO endorse bortezomib-containing regimens as frontline and relapse standards, with SC administration preferred.
• - Competitive yet penetrable: >10 US ANDAs and >15 EU MA holders exist; reliable supply, compliance credentials and sharp pricing can win tenders and emerging markets.
• - Strong cost edge: Typical 60–90% discount to originator enables fast access in price-sensitive, tender-driven geographies.